Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing

CRSP

CRISPR Therapeutics AG

Last Close
48.34
Nov 05 • 1:52 PM ET Dollar change-3.43 Percentage change(-6.63%)
Overview Compare Short Interest Financials Options Filings Dilution
Healthcare Biotechnology Switzerland Mid NASD
Peers: BEAM NTLA EDIT PRME VRTX IONS VIR ALNY INCY WVE
 | Held by: ARKE ARKK XBI IWM ARKG VXF IWN IBB VTWO SCHA
Scroll to Statements
Index
RUT
Market Cap
4.69B
Enterprise Value
3.20B
Income
-456.13M
Sales
25.17M
Book/sh
17.02
Cash/sh
23.43
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
-
IPO
Oct 19, 2016
P/E
-
Forward P/E
-
PEG
-
P/S
186.31
P/B
2.84
P/C
2.06
P/FCF
-
EV/EBITDA
-
EV/Sales
126.99
Quick Ratio
16.21
Current Ratio
16.21
Debt/Eq
0.47
LT Debt/Eq
0.46
Option/Short
Yes / Yes
EPS (ttm)
-4.75
EPS next Y
-3.55
EPS next Q
-1.17
EPS this Y
30.40%
EPS next Y
21.15%
EPS next 5Y
32.43%
EPS past 3/5Y
8.21% -4.10%
Sales past 3/5Y
43.09% 37.31%
EPS Y/Y TTM
14.92%
Sales Y/Y TTM
-34.34%
EPS Q/Q
1.19%
Sales Q/Q
1325.08%
Earnings
Nov 02 AMC
EPS/Sales Surpr.
-10.92% -14.12%
Insider Own
7.16%
Insider Trans
-1.38%
Inst Own
73.06%
Inst Trans
-1.47%
ROA
-19.00%
ROE
-25.60%
ROIC
-18.93%
Gross Margin
-693.22%
Oper. Margin
-2058.55%
Profit Margin
-1812.07%
SMA20
-4.85%
SMA50
-9.57%
SMA200
-8.45%
Trades
Shs Outstand
96.86M
Shs Float
90.05M
Short Float
18.26%
Short Ratio
10.88
Short Interest
16.44M
52W High
63.45 -23.81%
52W Low
44.12 9.57%
Volatility
5.13% 4.73%
ATR (14)
2.71
RSI (14)
41.15
Beta
1.90
Rel Volume
1.11
Avg Volume
1.51M
Volume
1,152,381
Perf Week
-10.90%
Perf Month
-7.65%
Perf Quarter
-9.67%
Perf Half Y
-7.78%
Perf YTD
-7.81%
Perf Year
-15.17%
Perf 3Y
-5.19%
Perf 5Y
-46.43%
Perf 10Y
218.05%
Recom
1.87
Target Price
82.74
Prev Close
51.78
Price
48.34
Change %
-6.63%
Consensus
Buy
Avg. Price Target
$82.74
Implied Upside
+71.1%
Analysts17incl. previous ratings
Rating Distribution9 Buy · 8 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 15, 2026Initiated
UBS logoUUBS
Neutral$52+7.6%
Jun 11, 2026Resumed
MS logoMMorgan Stanley
Equal-Weight$60+24.1%
Sep 18, 2025Initiated
JPM logoJJP Morgan
Overweight$70+44.8%
Feb 14, 2025Upgrade
EVR logoEEvercore ISI
In-line → Outperform$60 → $99+104.8%
Feb 12, 2025Upgrade
TD logoTTD Cowen
Sell → Hold$35-27.6%
Feb 03, 2025Initiated
HH.C. Wainwright
Buy$65+34.5%
Aug 06, 2024Reiterated
NNeedham
Buy$88 → $84+73.8%
Aug 02, 2024Initiated
RRodman & Renshaw
Buy$90+86.2%
Jun 28, 2024Resumed
GGuggenheim
Neutral
Feb 15, 2024Initiated
WWolfe Research
Peer Perform
Show Previous News
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kulkarni SamarthChief Executive OfficerOct 19 '26Sale49.7847,8372,381,326311,899Oct 20 05:35 PM
George SimeonDirectorOct 14 '26Option Exercise14.0030,000420,00030,000Oct 16 05:45 PM
George SimeonDirectorOct 14 '26Sale49.6314,514720,37315,486Oct 16 05:45 PM
KASINGER JAMES R.General Counsel and SecretaryOct 14 '26Sale49.261,04051,23095,857Oct 15 05:35 PM
Kulkarni SamarthChief Executive OfficerOct 14 '26Sale49.264,098201,867259,736Oct 15 05:35 PM
SIMEON GEORGEDirectorOct 14 '26Proposed Sale49.6314,514720,373Oct 14 04:16 PM
KASINGER JAMES R.General Counsel and SecretaryOct 06 '26Option Exercise13.621,99027,10496,774Oct 08 05:35 PM
KASINGER JAMES R.General Counsel and SecretaryOct 06 '26Sale60.041,990119,48194,784Oct 08 05:35 PM
JAMES KASINGEROfficerOct 06 '26Proposed Sale60.041,990119,481Oct 06 04:47 PM
KASINGER JAMES R.General Counsel and SecretarySep 22 '26Option Exercise13.6210,400141,648105,184Sep 24 05:35 PM
KASINGER JAMES R.General Counsel and SecretarySep 22 '26Sale60.2410,400626,46094,784Sep 24 05:35 PM
JAMES KASINGEROfficerSep 22 '26Proposed Sale60.2410,400626,460Sep 22 04:42 PM
Behbahani AliDirectorSep 17 '26Option Exercise14.0030,000420,00030,316Sep 21 06:40 PM
Behbahani AliDirectorSep 17 '26Sale57.0913,679780,93516,637Sep 21 06:40 PM
ALI BEHBAHANIDirectorSep 17 '26Proposed Sale57.0913,679780,935Sep 17 04:08 PM
Patel NaimishChief Medical OfficerMay 29 '26Sale55.623,786210,57719,357Jun 01 05:35 PM
KASINGER JAMES R.General Counsel and SecretaryMar 23 '26Sale46.783,182148,85494,308Mar 24 05:38 PM
Kulkarni SamarthChief Executive OfficerMar 23 '26Sale46.7810,020468,736255,501Mar 24 05:37 PM
Prasad RajuChief Financial OfficerMar 23 '26Sale46.783,708173,46015,565Mar 24 05:37 PM
Patel NaimishChief Medical OfficerMar 16 '26Sale48.263,150152,01913,143Mar 17 05:37 PM
Prasad RajuChief Financial OfficerMar 16 '26Sale48.269,869476,27813,773Mar 17 05:37 PM
KASINGER JAMES R.General Counsel and SecretaryMar 16 '26Sale48.263,450166,49791,240Mar 17 05:35 PM
Kulkarni SamarthChief Executive OfficerMar 16 '26Sale48.2610,349499,443245,834Mar 17 05:35 PM
KASINGER JAMES R.General Counsel and SecretaryMar 11 '26Sale52.802,800147,84087,815Mar 12 05:35 PM
Kulkarni SamarthChief Executive OfficerMar 11 '26Sale52.809,798517,334235,558Mar 12 05:35 PM
Kulkarni SamarthChief Executive OfficerFeb 19 '26Sale52.586,967366,325226,106Feb 20 05:36 PM
KASINGER JAMES R.General Counsel and SecretaryFeb 19 '26Sale52.582,112111,04985,115Feb 20 05:35 PM
Prasad RajuChief Financial OfficerJan 22 '26Option Exercise45.1534,9721,578,98641,739Jan 26 05:35 PM
Prasad RajuChief Financial OfficerJan 22 '26Sale60.1934,9722,104,9656,767Jan 26 05:35 PM
Kulkarni SamarthChief Executive OfficerJan 22 '26Sale60.2360,0003,613,800134,201Jan 22 05:55 PM
Kulkarni SamarthChief Executive OfficerJan 20 '26Sale51.7530,0001,552,498194,201Jan 22 05:55 PM
Samarth KulkarniOfficerJan 22 '26Proposed Sale60.8160,0003,648,600Jan 22 05:15 PM
RAJU PRASADOfficerJan 22 '26Proposed Sale60.1934,9722,105,070Jan 22 04:03 PM
Samarth KulkarniOfficerJan 20 '26Proposed Sale52.6130,0001,578,300Jan 20 05:11 PM
Prasad RajuChief Financial OfficerJan 06 '26Option Exercise44.9729,7001,335,63036,467Jan 08 05:35 PM
Prasad RajuChief Financial OfficerJan 06 '26Sale60.1629,7001,786,6366,767Jan 08 05:35 PM
RAJU PRASADOfficerJan 06 '26Proposed Sale60.1629,7001,786,636Jan 06 05:11 PM
Prasad RajuChief Financial OfficerDec 22 '25Sale55.9510,000559,5496,767Dec 23 05:33 PM
RAJU PRASADOfficerDec 22 '25Proposed Sale55.9510,000559,548Dec 22 04:20 PM
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
CEO & ChairmanDr. Samarth Kulkarni Ph.D.
M.D.Dr. Naimish Patel C.M.
Co-FounderMr. Shaun Foy CFA
Co-Founder & Scientific Advisory Board MemberDr. Emmanuelle Marie Charpentier Ph.D.
Scientific Founder & Advisory Board MemberDr. Craig C. Mello Ph.D.
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)